Position:Home> News> Our News


Baheal Pharma Made Nishu Duloxetine Hydrochloride Enteric Soluble Capsules Selected for National VBP

On February 3, the result of the fourth batch of national volume-based procurement (VBP) was announced, and the competition results of the antidepressant drug duloxetine were settled. The results show that Qingdao Baheal Pharma...


Focus on Qingdao Two Sessions |Group Chairman Fu Gang Advises on the Development of Qingdao Health Industry

From January 10th, Qingdao officially entered the annual "two sessions time". Delegates and members focus on health, education, transportation, urban construction and other areas of people's livelihood and economic concerns, an...


Baheal Has Won Two Awards

On December 19, Baheal Pharmaceutical Group was awarded the 2020 Shandong Province "Quality Lu Medicine" Construction Demonstration Enterprise Award by Shandong Province Pharmaceutical Industry Association; on December 21, Qing...


Baheal Pharma's New High-end Generic Drug Duloxetine Capsules Approved for Marketing

Qingdao Baheal Pharmaceutical Co. Ltd. (hereinafter referred to as "Baheal Pharma") announced that its Duloxetine Hydrochloride Enteric Capsules have been approved by the National Medical Products Administration (NMPA) with the...


Baheal commercialization platform has reached a new cooperation with Astellas

 Beijing, December 16, 2020 – Astellas Pharma (China) Inc. and Baheal Medical Inc. held  XOSPATA® (gilteritinib) import and distribution strategic signing ceremony. This will lay the foundation for the first cooperation betwee...


Baheal commercialization platform partnered with Abbott to expand the vast market in China

Shanghai, November 5, 2020 – Abbott and Qingdao Baheal Medical INC. formally signed an agreement in Shanghai during the Expo. Through the omni-channel commercial platform, Baheal will help high-quality products and efficient tr...


12345...18 Items